Branaplam is under investigation in clinical trial NCT02268552 (An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)). The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Branaplamum. Its PubChem CID is 135565042.
Branaplam
| CAS No | 1562338-42-4 |
|---|---|
| Molecular Formula | C22H27N5O2 |
| Molecular Weight | 393.5 g/mol |
| Synonyms | 5-(1H-pyrazol-4-yl)-2-[6-(2,2,6,6-tetramethylpiperidin-4-yl)oxypyridazin-3-yl]phenol |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Branaplam is under investigation in clinical trial NCT02268552 (An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)). The directory classifies it as a discontinued API with a synthetic source/manufacturing origin.
The listed CAS number is 1562338-42-4.
The listed molecular formula is C22H27N5O2.
The listed molecular weight is 393.5 g/mol.
5-(1H-pyrazol-4-yl)-2-[6-(2,2,6,6-tetramethylpiperidin-4-yl)oxypyridazin-3-yl]phenol.
The source lists Branaplamum.